in the *IDH* wild-type group. In the *IDH* mutated group, the *ATRX* status allows a prognostic subclassification. These markers plus 1p/19q codeletion argue for a molecularly based definition of all AG, with AOA no longer considered as a separate category.

© 2014 American Academy of Neurology

1. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of *MGMT* promoter methylation in gliomas depends on *IDH1* mutation. *Neurology* 2013;81:1515–1522.
2. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. *J Clin Oncol* 2009;27:5874–5880.
3. van den Bent MJ, Brandes AA, Taphoorn M, et al. Adjuvant procarbazine, lomustine and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. *J Clin Oncol* 2013;31:344–350.
4. Wick W, Platten M, Meisner C, et al; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol* 2012;13:707–715.
5. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent *ATRX*, *CIC*, *FUBP1* and *IDH1* mutations refine the classification of malignant gliomas. *Oncotarget* 2012;3:709–722.
6. Wiestler B, Capper D, Holland-Letz T, et al. *ATRX* loss refines the classification of anaplastic gliomas and identifies a subgroup of *IDH* mutant astrocytic tumors with better prognosis. *Acta Neuropathol* 2013;126:443–451.
7. Koelsche C, Sahm F, Capper D, et al. Distribution of *TERT* promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathol* 2013;126:907–915.

CORRECTION

A Survey of Cluster Headache (CH) Sufferers Using Vitamin D3 as a CH Preventative (P1.256)

In the abstract “A Survey of Cluster Headache (CH) Sufferers Using Vitamin D3 as a CH Preventative (P1.256)” by Peter Batcheller (*Neurology* 2014;82:P1.256), there is an error in the disclosures. It should have read: “Mr. Batcheller has nothing to disclose.” The AAN staff regrets the error.

Author disclosures are available upon request (journal@neurology.org).

Neurology®

A Survey of Cluster Headache (CH) Sufferers Using Vitamin D3 as a CH Preventative (P1.256)

Neurology 2014;82;2148

DOI 10.1212/WNL.0000000000000557

This information is current as of June 9, 2014

**Updated Information &
Services**

including high resolution figures, can be found at:
<http://n.neurology.org/content/82/23/2148.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.